BCRX
BCRX clinical trials: BIOCRYST PHARMACEUTICALS INC
Every trial on ClinicalTrials.gov where BIOCRYST PHARMACEUTICALS INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 56
- Trials linked
- 54
- As lead sponsor
- 2
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
BCRX on the catalyst calendar · BCRX registry changes
- Primary completion Dec 2026Sponsor estimatePhase 1NCT06539507A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725BioCryst Pharmaceuticals · Netherton SyndromeActive, not recruitingBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2025ActualPhase 2NCT05741346Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal HemoglobinuriaBioCryst Pharmaceuticals · Paroxysmal Nocturnal HemoglobinuriaTerminatedBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 23, 2022ActualPhase 2NCT05162066Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A...BioCryst Pharmaceuticals · Complement 3 GlomerulopathyTerminatedBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 18, 2023ActualPhase 2NCT05116787BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor TherapyBioCryst Pharmaceuticals · Paroxysmal Nocturnal Hemoglobinuria (PNH)TerminatedBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 14, 2023ActualPhase 2NCT05116774BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor TherapyBioCryst Pharmaceuticals · Paroxysmal Nocturnal Hemoglobinuria (PNH)TerminatedBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2010ActualPhase 3NCT01224795A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.BioCryst Pharmaceuticals · InfluenzaWithdrawnBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 3NCT00486980Intramuscular Peramivir for the Treatment of Uncomplicated InfluenzaBioCryst Pharmaceuticals · InfluenzaWithdrawnBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 17, 2026ActualPhase 1NCT07228559A Study of Avoralstat In Participants With Diabetic Macular EdemaBioCryst Pharmaceuticals · Diabetic Macular Edema (DME)TerminatedBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 11, 2024ActualPhase 3NCT05453968Berotralstat Treatment in Children With Hereditary AngioedemaBioCryst Pharmaceuticals · Hereditary AngioedemaActive, not recruitingBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2031Sponsor estimatePhase 3NCT04933721Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat StudiesBioCryst Pharmaceuticals · Hereditary AngioedemaEnrolling by invitationBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2016ActualPhase 2/Phase 3NCT0230362612-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE AttacksBioCryst Pharmaceuticals · Hereditary AngioedemaCompletedBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 4, 2023ActualPhase 2NCT04702568A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)BioCryst Pharmaceuticals · Paroxysmal Nocturnal HemoglobinuriaTerminatedBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 11, 2024ActualPhase 1NCT06100900Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)BioCryst Pharmaceuticals · Paroxysmal Nocturnal HemoglobinuriaCompletedBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 8, 2021ActualPhase 3NCT03873116Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in JapanBioCryst Pharmaceuticals · Hereditary Angioedema, HAECompletedBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 10, 2019ActualPhase 3NCT03485911Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAEBioCryst Pharmaceuticals · Hereditary AngioedemaCompletedBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 27, 2022ActualPhase 2/Phase 3NCT03472040A Long Term Safety Study of BCX7353 in Hereditary AngioedemaBioCryst Pharmaceuticals · Hereditary AngioedemaCompletedBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 11, 2020ActualPhase 1/Phase 2NCT04330534First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNHBioCryst Pharmaceuticals · Paroxysmal Nocturnal HemoglobinuriaCompletedBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2019ActualPhase 1NCT03800173A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430BioCryst Pharmaceuticals · Marburg Virus DiseaseCompletedBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2021ActualPhase 1NCT03891420A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19BioCryst Pharmaceuticals · COVID-19TerminatedBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2019ActualPhase 2NCT03240133Study of BCX7353 as a Treatment for Attacks of Hereditary AngioedemaBioCryst Pharmaceuticals · Hereditary Angioedema (HAE)CompletedBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2017ActualPhase 2NCT02870972Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary AngioedemaBioCryst Pharmaceuticals · Hereditary Angioedema (HAE)CompletedBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2018ActualPhase 3NCT02635724Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated InfluenzaBioCryst Pharmaceuticals · InfluenzaCompletedBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 28, 2019ActualPhase 3NCT02369159Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated InfluenzaBioCryst Pharmaceuticals · InfluenzaCompletedBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2008ActualPhase 3NCT00610935Intramuscular Peramivir in Subjects With Uncomplicated Acute InfluenzaBioCryst Pharmaceuticals · InfluenzaTerminatedBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT04428632Oral Berotralstat Expanded Access ProgramBioCryst Pharmaceuticals · Hereditary AngioedemaApproved for marketingBCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 31 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner